Athira Pharma, Inc. (ATHA)


-0.13 (-6.44%)
Symbol ATHA
Price $1.89
Beta 2.815
Volume Avg. 0.15M
Market Cap 71.923M
Shares () -
52 Week Range 1.86-4.41
1y Target Est -
DCF Unlevered ATHA DCF ->
DCF Levered ATHA LDCF ->
ROE -43.61% Strong Sell
ROA -46.82% Strong Sell
Operating Margin -
Debt / Equity 0.95% Neutral
P/E -0.63
P/B 0.39 Neutral


Consensus EPS

Upgrades & Downgrades

Latest ATHA news

Dr. Mark J. Litton M.B.A., MBA, Ph.D.
NASDAQ Global Select

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.